Clinical Study to Evaluate Device’s Ability to Prevent Amputation and Promote Wound Healing in Patients with No Other Options CORRECTION…by LimFlow SA PARIS–(BUSINESS WIRE)–First paragraph, last sentence should read: The successful first case was performed by Mark Archie, MD, principal investigator for the PROMISE II trial at Harbor-UCLA Medical Center, […]
Tag: LimFlow
LimFlow Announces Positive Six-Month Data From Promise I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-Option Patient Population
Results Presented Today at Vascular Interventional Advances (VIVA) Conference PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the presentation of positive six-month data from the full patient cohort in […]
LimFlow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption for the PROMISE II pivotal study of the LimFlow Percutaneous Deep […]
LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment
PARIS–(BUSINESS WIRE)–LimFlow SA, developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced it has secured €27 million ($33.5 million) in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with continued participation from existing round B investors Bpifrance, the French […]
LimFlow Taps a New Chairman of the Board and Expands Senior Management Team
LimFlow Nominates Pierre Guyot as Chairman of Board of Directors and Expands Senior Management Team PARIS–(BUSINESS WIRE)– LimFlow SA, a Paris-based medical device company dedicated to transforming treatment options for Critical Limb Ischemia (CLI), announced today changes to their board of directors by naming Pierre Guyot as the new chairman of […]
LimFlow Announces Publication Of Positive Results From Pilot Study Of Limflow Percutaneous Deep Vein Arterialization (pDVA) System
PARIS–(BUSINESS WIRE)–LimFlow SA today announced publication of positive results from the pilot study of the LimFlow Percutaneous Deep Vein Arterialization System (pDVA) in the July issue of the Journal of Endovascular Therapy. The paper is entitled “Midterm Outcomes from a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option […]
LimFlow Announces First Patient Treated In U.S. Feasibility Study And Commencement Of International Post-Market Study
PARIS–(BUSINESS WIRE)–LimFlow SA today announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System, a novel, purely percutaneous device for the treatment of end-stage critical limb ischemia (CLI) when all other revascularization efforts have been exhausted. The first patient was treated […]
Europe’s LimFlow Hires a COO and Opens Bay Area Office
LimFlow Expands Senior Management Team And Opens Silicon Valley Office PARIS–(BUSINESS WIRE)–LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD), today announced the expansion of the company’s senior management team. Sophie Humbert, PhD, has been appointed […]